Mayne Pharma Group Limited

ASX MYX.AX

Mayne Pharma Group Limited Dividend Yield on January 14, 2025: 0.00%

Mayne Pharma Group Limited Dividend Yield is 0.00% on January 14, 2025, a -100.00% change year over year. Dividend yield measures the dividend per share relative to stock's price value; higher yield suggests higher dividend return.
  • Mayne Pharma Group Limited 52-week high Dividend Yield is 12.55% on June 17, 2024, which is 0.00% below the current Dividend Yield.
  • Mayne Pharma Group Limited 52-week low Dividend Yield is 0.00% on January 14, 2025, which is 0.00% below the current Dividend Yield.
  • Mayne Pharma Group Limited average Dividend Yield for the last 52 weeks is 4.09%.
Key data
Date Dividend Yield Free Cash Flow Yield Earnings Yield Enterprise Value (EV)
Market news
Loading...
ASX: MYX.AX

Mayne Pharma Group Limited

CEO Mr. Shawn Patrick O'Brien B.Sc
IPO Date June 29, 2007
Location Australia
Headquarters 1538 Main North Road
Employees 850
Sector Health Care
Industries
Description

Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe and Asia. The company operates through four segments: Metrics Contract Services, International, Branded Products, and Portfolio Products. It provides oral drug delivery systems; and contract pharmaceutical development, manufacturing, and analytical services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.

Similar companies

MSB.AX

Mesoblast Limited

USD 1.58

-2.06%

GEM.AX

G8 Education Limited

USD 0.79

2.65%

NAN.AX

Nanosonics Limited

USD 2.01

-0.68%

StockViz Staff

January 15, 2025

Any question? Send us an email